Hanmi Pharmaceuticals
Hanmi Pharmaceuticals · Hanmi pharmaceuticals
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hanmi Pharmaceuticals as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:15 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04510415 · Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKIHanmi Pharmaceutical Company Limited · terminated · Non Small Cell Lung Cancer · study director
- Ph2NCT04044170 · Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationHanmi Pharmaceutical Company Limited · terminated · NSCLC · study director
- Ph1NCT03374241 · A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)Hanmi Pharmaceutical Company Limited · completed · Obesity · study director
- Ph1NCT02302443 · A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470Hanmi Pharmaceutical Company Limited · completed · Diabetes Mellitus · study director
- Ph2NCT02075281 · Effect of LAPS-Exendin on Body Weight in Obese PopulationHanmi Pharmaceutical Company Limited · completed · Obesity · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.